mlkrborn
14年前
Solta Medical beats by $0.04, beats on revs; guides FY12 revs in-line (SLTM) : Reports Q2 (Jun) earnings of $0.04 per share, $0.04 better than the Capital IQ Consensus Estimate of ($0.00); revenues rose 29.1% year/year to $37.3 mln vs the $36.09 mln consensus. Co raises guidance for FY12, sees FY12 revs of $142-144 mln up from $140-143 mln vs. $144.12 mln Capital IQ Consensus Estimate. Non-GAAP gross margin is now estimated to be in the range of 64% to 67% for the full year 2012 as compared to the Company's previously issued range of 63% to 66%. Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP gross margin for the six months ended June 30, 2012 was 67.5%. The outlook for positive non-GAAP EBITDA for every quarter and for the full-year 2012 remains unchanged. Non-GAAP EBITDA excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP EBITDA for the six months ended June 30, 2012 was $4.7 million.
loniee
16年前
Solta Medical Completes Acquisition of Aesthera Corporation
HAYWARD, Calif., March 1 /PRNewswire-FirstCall/ --
Solta Medical, Inc. , a global leader in the medical aesthetics market, today announced the successful completion of its acquisition of Aesthera Corporation. The transaction brings together the Isolaz(TM) brand of products for the treatment of acne with Solta's leading brands for skin tightening and skin resurfacing, Thermage(TM) and Fraxel(TM).
"We are delighted with the swift completion of the acquisition of Aesthera which we announced earlier this week," said Stephen J. Fanning, Chairman of the Board, President, and CEO of Solta Medical. "We look forward to successfully integrating the Isolaz brand into our global sales and marketing organization, and providing dermatologists and aesthetic physicians with yet another superior solution for their patients." Under the agreement, Solta acquired Aesthera for consideration of $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. In addition, there are $10 million of stretch milestones which would be paid to Aesthera shareholders if Aesthera achieves revenue ranging from $14 to $21 million in the twelve months beginning April 1, 2010. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months, and becomes increasingly accretive to Solta Medical shareholders as Aesthera achieves the higher milestone revenue and payments.
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address aging skin under the industry's two premier brands: Thermage® and Fraxel®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed in nearly 80 countries. Thermage and Fraxel are the perfect complement for any aesthetic practice. For more information about Solta Medical, call 1-877-782-2286 or log on to http://www.solta.com/.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the possibility that the market for the sale of these new products and initiatives does not develop as expected and the remaining risks and uncertainties with the integration process, and the risks relating to economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for Solta's products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2008, its Form10-Q for the quarter ended September 30, 2009, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Web Site: http://www.solta.com/ DATASOURCE: Solta Medical, Inc.
CONTACT: Jack Glenn, Chief Financial Officer of Solta Medical, Inc.,+1-510-786-6890; or investors, Doug Sherk, dsherk@evcgroup.com, EVC Group,+1-415-896-6820, for Solta Medical, Inc.
Web Site: http://www.solta.com/
THUMBS
16年前
Solta Medical to Raise $17.2 Million in Private Placement
Provides Preliminary Q4 2009 Revenue Estimate of $28.0 Million to $29.0 Million
HAYWARD, Calif., Jan. 8 /PRNewswire/ --
Solta Medical, Inc. (NASDAQ:SLTM) today announced that it has obtained commitments from accredited institutional investors to purchase approximately $17.2 million of its common stock and warrants in a private placement. The financing was led by existing investor Longitude Capital and new investor Great Point Partners along with participation from other existing investors. Solta has entered into a securities purchase agreement with the investors pursuant to which Solta will sell an aggregate of 8,259,704 shares of its common stock and warrants to purchase up to 4,264,852 additional shares of common stock. Each unit, consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, will be sold for a purchase price of $2.02, equal to the closing price of the common stock as reported on the Nasdaq Global Market on January 6, 2010. The private placement is subject to customary closing conditions and is expected to close within a week's time. Morgan Keegan & Company, Inc. acted as the sole placement agent and FTN Equity Capital Markets Corporation acted as a financial advisor
Proceeds from the private placement are expected to be used for general corporate and working capital purposes, as well as to opportunistically pursue strategic initiatives
The warrants will be exercisable at an exercise price equal to $2.121, which represents a 5% premium over the closing price of the common stock as reported on the Nasdaq Global Market on January 6, 2010. The warrants are exercisable commencing on the six-month anniversary of the closing and will expire five and a half years from the date of issuance
The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements. Solta has agreed to file a registration statement under the Securities Act covering the resale of the shares of common stock, including shares issuable upon exercise of the warrants, to be sold in the private placement
Solta today also announced a preliminary estimate of revenue for the fourth quarter of 2009 to be in the range of $28.0 million to $29.0 million. In addition, the company reiterated that it expects to:
-- Generate positive non-GAAP EBITDA for the fourth quarter and the full year 2009; and -- Achieve a non-GAAP gross margin in the range of 64% to 66% for the full year 2009, excluding non-cash amortization charges and non-cash purchase price related charges
Non-GAAP Presentation
To supplement the preliminary revenue estimate presented on a GAAP basis, management has provided non-GAAP EBITDA and non-GAAP gross margin that exclude the impact of purchase price related charges, severance costs, merger related costs, extraordinary loss on investments and stock-based compensation expenses, all net of income taxes. Solta believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of Solta's ongoing operating results and trends, compared with historical results. This presentation is also consistent with management's internal use of the measures, which it uses to measure the performance of ongoing operating results, against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with Solta's consolidated financial statements prepared in accordance with GAAP and the reconciliation of actual GAAP and non-GAAP financial measures to be provided in Solta's upcoming earnings release for the fourth quarter and year ended December 31, 2009
This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Any offering of Solta Medical, Inc. common stock under the resale registration statement will be made only by means of a prospectus. For additional information, please refer to Solta Medical's current reports on Form 8-K to be filed with the Securities and Exchange Commission with respect to the private placement
About Solta Medical, Inc
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians
The company offers products to address aging skin under the industry's two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed worldwide. Thermage and Fraxel are the perfect complement for any aesthetic practice. Our products are available in over 100 countries. For more information about Solta Medical, call 877-782-2286 or log on to http://www.solta.com/
THUMBS
17年前
Solta Medical Reports Third Quarter 2009 Results
Provides full year 2009 revenue guidance of $95 million to $98 million
HAYWARD, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (NASDAQ:SLTM), a global leader in the medical aesthetics market, today announced results for the third quarter ended September 30, 2009. Revenue for the quarter was in-line with the preliminary forecast provided on September 28th.
Revenue for the third quarter was $17.8 million, an increase of approximately $4.7 million, or 36%, as compared to the third quarter 2008 reflecting increased revenue as a result of the acquisition of Reliant Technologies, Inc. on December 23, 2008, and partially offset by production and regulatory approval delays on new products during the third quarter.
"As we have previously disclosed, we received 510K clearance for the Fraxel re:store DUAL system in mid-October and resolved our production delays on the Thermage CPT system at the end of the third quarter. We are fulfilling back orders from customers and shipping both products," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical. "Our illumiNATION tour continues to bring these latest breakthroughs in Thermage and Fraxel systems directly to physicians as it makes it way from city-to-city across the U.S. and Europe. The tour has generated a very enthusiastic response to our new products by physicians, prospective patients, and the media. As a result, we are gaining momentum in the market place," added Mr. Fanning.
Solta Medical's reported results for the third quarter of 2009 include non-cash purchase price related charges, primarily amortization of acquired intangible assets, of $1.2 million and non-cash stock based compensation charges of $0.8 million. The GAAP net loss for the quarter including these charges was $6.2 million, or $0.13 per share as compared to a net loss of $1.1 million, or $0.05 per share reported for the third quarter of 2008. The non-GAAP net loss for the quarter excluding these charges was $4.2 million, or $0.09 per share as compared to non-GAAP net income of $0.7 million, or $0.03 per share reported for the third quarter of 2008.
Financial Goals for 2009
The Company updated its financial goals for 2009 as follows:
-- Revenue for the year in the range of $95 million to $98 million -- Realize up to $25 million in cost synergies as a result of the acquisition of Reliant Technologies, Inc. This represents an increase of $6 million from the originally stated goal in January 2009 of $19 million in cost synergies.
-- Generate positive EBITDA for the full year 2009
-- Achieve a non-GAAP gross margin in the range of 64% to 66% for the full year 2009 excluding non-cash amortization charges and non-cash purchase price related charges.
Non-GAAP Presentation
To supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of purchase price related charges, severance costs, merger related costs, extraordinary loss on investments, and stock-based compensation expenses, all net of income taxes. The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results. This presentation is also consistent with management's internal use of the measures, which it uses to measure the performance of ongoing operating results, against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.
Conference Call Information
Solta Medical will host a conference call and webcast today, Tuesday, November 3, 2009, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 877-941-1465 for domestic participants and 480-629-9678 for international participants.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers. Both callers will need to use the Passcode 4171632#. To access the live webcast of the call, go to Solta Medical's website at http://www.solta.com/ and click on Investor Relations. An archived webcast will also be available at http://www.solta.com/.
About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective anti-aging solutions for patients which enhance and expand the practice of medical aesthetics for physicians.
The company offers products to address aging skin under the industry's two premier brands: Thermage(R) and Fraxel(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Since 2002, over one million Thermage and Fraxel procedures have been performed worldwide. Thermage and Fraxel are the perfect complement for any aesthetic practice. Our products are available in over 100 countries. For more information about Solta Medical, call 877-782-2286 or log on to http://www.solta.com/.
THUMBS
17年前
Solta Medical, Inc. Announces Third Quarter 2009 Results Release Date and Conference Call
Oct 21, 2009 1:45:00 PM
HAYWARD, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it will release its financial results for the third quarter ended September 30, 2009 after the market close on Tuesday, November 3, 2009. The Company will also host a conference call and webcast on Tuesday, November 3, 2009, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 877-941-1465 for domestic participants and 480-629-9678 for international participants.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers. Callers will need to use the Passcode 4171632#. To access the live webcast of the call, go to Solta Medical's website at www.solta.com and click on Investor Relations. An archived webcast will also be available at www.solta.com.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
BettingAngles
13年前
MissionIR
13年前
jump1
13年前
Penny Roger$
14年前
kuwlness
16年前
wesley_
16年前
Twilson
17年前
メールアドレスで登録
